The Fox Focus Spring/Summer 2016 | Page 12

THE FOX FOCUS... “When We Share Our Commitment to a Cure, Our Passion Comes Through” As the Michael J. Fox Foundation and the Parkinson’s Action Network announce plans to integrate and operate as a single entity, Parkinson’s patients and advocates (and good friends) Steve DeWitte and Israel Robledo talk to MJFF about the power of the patient voice and their hopes for the future of Parkinson’s public policy. MJFF: What was your path from being diagnosed with Parkinson’s to becoming leaders in the PD community? Israel: For me it was first about coming to terms with my diagnosis because I was only 42. I had work and family responsibilities to fulfill. I went through depression, where the focus was on me and my concerns about the advanced stages of the disease. But after about nine months, I turned a corner and decided the focus would be on supporting others and finding a cure. Steve: I was about 46 when I showed symptoms. I didn’t know what PD was. I did a lot of research online. That’s when I first connected with Israel, because he was writing a great blog. I went from learning to a more proactive stance. I was diagnosed in 2005 and soon after, I started a support group with eight people. Now we have three chapters and more than 150 people. Some of them have gone on to raise funds for research, take part in clinical trials or speak with legislators. MJFF: What is it like to see results emerge from your advocacy? Israel: I always had an interest in the politi- cal process, and I enjoy talking to my congressman and my senator to share why research is needed. One day my representative 12 THE FOX FOCUS said to me, “I think of you when Parkinson’s comes up on the floor. You have showed me what it’s like to have Parkinson’s.” Steve: I formed three principles, or areas, that patients must take on themselves — education, clinical trials and advocacy. There’s no better way to say, “This is why we need a treatment,” than to have a patient tell that story. MJFF: You’ve also both taken part in clinical trials. Why is research participation important to you? I